NY-BCW
10.1.2020 22:21:10 CET | Business Wire | Press release
Harold Burson, once a 14-cents-per-column-inch stringer for a Memphis newspaper, who reported the Nuremberg Trial for the Army radio network in Europe and whose one-man consultancy became by 1983 the world’s largest public relations firm, died on January 10, 2020. He was 98.
Burson played a leading role in transforming the practice of public relations from a cottage industry to a global business that engaged thousands of employees. He stepped down as Chief Executive Officer of Burson-Marsteller in 1988 but continued in an active capacity for more than a quarter century and came to work nearly every day well into his 90s.
In 1999, a survey by PRWeek, a leading public relations industry trade publication, named Burson as “the century’s most influential PR figure.” This recognition reflected his role as counselor to and confidant of corporate chief executive officers, government leaders and heads of public sector institutions.
His PRWeek citation read:
“The architect of the largest public relations agency in the world today (1999), Burson-Marsteller Chairman Harold Burson’s contribution is immense in many other ways besides. He started practicing the concept of integrated marketing decades before the term was even invented. He brought PR into the advertising business at Young & Rubicam as an equal (it’s arguably never been achieved again). His development of training programs set the benchmark that other agencies have only recently caught up with. He has personally sponsored and supported programs, industry bodies, universities and charities to improve the profession. His mentoring of talent has spawned a whole wave of ex-Burson PR agency start-ups. He created a unique Burson culture that still unites former employees. And, last but not least, his personal counsel has enlightened the thinking of boardrooms at many Fortune 100 companies and across the globe.”
He was a strong proponent of the corporation’s role in society as a social entity, insisting that the mission of a corporation was to deliver a good product at a fair price, treat its employees fairly in terms of compensation and retirement, deal fairly with suppliers, support essential community activities in areas where it operated, and reward its stockholders with a fair return on their investment. But he warned that the principal objective of the corporation was to make a profit that enabled it to fund its responsibilities as a social entity.
Born February 15, 1921, in Memphis, Tennessee, the son of emigrants from Leeds, Yorkshire, England, he started school in the third grade and graduated from high school at age 15. He enrolled at the University of Mississippi (Ole Miss) knowing that his campus correspondent stringer job for the Memphis Commercial Appeal would cover his college tuition and expenses. Six months after graduation, he accepted a public relations position at a large engineering and architectural firm when, as he said, “they doubled my salary from $25 to $50 per week and gave me the use of a car.”
Burson enlisted in the United States Army in 1943 and became part of an engineer combat group in Europe. In 1945, he was transferred to the news staff of the American Forces Network a month before the war ended in Europe.
Later in 1945, he was assigned to report on the Nuremberg Trial and was the only reporter to obtain an interview during the trial with Associate Justice Robert H. Jackson, the chief American prosecutor. Although Justice Jackson had vowed not to grant interviews, Burson argued that his audience, the American GIs who fought the war, were entitled to hear firsthand from the chief American prosecutor. Only 24-years-old when the Nuremberg Trial began, Burson was believed to have been the last living reporter who covered the historic trial.
Following his discharge from the Army in 1946, Burson opened a public relations firm in New York in “a tiny nook in a client’s office” next to the desk of a part-time executive assistant. Never having heard the word “differentiation” used in a competitive sense, he described his firm as specializing in business-to-business clients. The firm he worked for before his Army service was in that category and he quickly learned that few business-to-business companies employed public relations consultants.
In 1952, Burson’s firm had a staff of five when a friend at The New York Times, responding to a query from the owner of a Chicago advertising agency, recommended Burson for a Pittsburgh-based project. Through this opportunity, he came to meet William A. (Bill) Marsteller, with whom his name was linked by a hyphen for 65 years. The Burson firm was hired for the project – to publicize the purchase by Rockwell Manufacturing Company of the first helicopter to be used for executive travel. Rockwell subsequently became a full-fledged client.
Shortly thereafter, Marsteller introduced Burson to the chief executive officer of another client, Clark Equipment Company, which led to still more business. The affiliation with Marsteller worked so well that Burson proposed establishing a new company jointly owned by the two parties. It took the name Burson-Marsteller and opened March 2, 1953 with offices in New York and Chicago and offered “integrated communications services” to business-to-business clients, believed to be the first to do so.
In speeches and articles, Burson has cited two “defining moments” that accounted for the company’s rapid growth. The first was the creation of the European Common Market in the late 1950s. Burson’s firm was the second to establish an office in Europe – in Geneva, Switzerland in early 1961 – and announced its intention to become a global operation over the next quarter century. Though still a speck on the public relations spectrum in the U.S., Burson-Marsteller became known as “the other international public relations firm.” During the 1960s, its annual revenues surged tenfold, from $410,000 to $4.4 million.
The firm’s second defining moment was its selection in 1970 by General Motors (GM) to be its sole public relations counsel, a response to allegations that GM hired private investigators to follow the self-appointed public watchdog, Ralph Nader, after his scathing book questioning the safety of GM’s highly touted Chevrolet Corvair. After GM’s CEO was called to testify before a Congressional committee, the company, on instructions from its board of directors, hired an outside public relations firm to consult with management. Competing against the two largest U.S. firms, Burson-Marsteller was chosen for the assignment, which continued for more than a decade.
During the 1970s, the firm’s revenues increased from $5.2 million to $28.3 million. It added about a dozen new offices in Europe, including London, Paris, Brussels and Frankfurt, and in Asia, in Hong Kong, Tokyo and Singapore. Its clients included both American multinationals and local businesses.
In 1979, Burson engineered the merger of Burson-Marsteller and Marsteller Advertising with the global advertising giant Young & Rubicam, becoming a member of its seven-person executive committee. At the time of the merger, Burson-Marsteller had revenues of $28.3 million and 16 offices. Four years later, when Burson-Marsteller became the world’s largest public relations firm, it had revenues of $63.8 million and 30 offices, including branches in Latin America, Australia and the Middle East.
One of the firm’s specialties was crisis management, ranging from the major Tylenol recalls in 1982 and 1985, which were often referred to as models for corporate management in times of crisis, to the celebrated introduction of “New Coke” and the reintroduction of Coca-Cola Classic in 1985, an undertaking in which Burson himself was a prime participant. After the “New Coke” debacle and the re-introduction of Coca-Cola Classic, he summarized the exercise as “[w]e got a hole-in-one after the ball hit the tree.” The firm also represented Union Carbide in the aftermath of the discharge of toxic chemicals at its plant in Bhopal, India; Pan Am Airways after the Lockerbie (Scotland) crash; and Dow Corning following the U.S. Food and Drug Administration’s decision to ban silicone breast implants. Burson-Marsteller also had a long-time active role in representing the Olympic Games and its corporate sponsors.
Burson received numerous awards from public relations organizations including Hall of Fame designations by the Public Relations Society of America, the Arthur W. Page Society, PRWeek, PR News, the Institute of Public Relations, the Alan Campbell Johnson Award (England), as well as numerous citations by colleges and universities in the United States, Europe and China. He was awarded an honorary degree by Boston University in 1988, and a chair in public relations was established in his name in 1995. He is also in the Hall of Fame at his alma mater, Ole Miss, and shares a place in the Humes High School Hall of Fame in Memphis with Elvis Presley.
He was active in numerous public service organizations, principally the John F. Kennedy Center for the Performing Arts. As a board member of Kennedy Center Productions, he negotiated Japan’s $3 million bicentennial gift in 1976 to construct the Terrace Theater. He also was instrumental in establishing the Kennedy Center Corporate Fund in 1977.
Another of his interests was economic education. He was chairman of the Council on Economic Education in the early 1990s and was an active member of the Economic Club of New York since 1979, including serving as chairman of the organization’s centennial dinner in 2007. In conjunction with the dinner, he proposed the creation of a Centennial Society composed of members who contribute at least $10,000 to the establishment of a club endowment fund.
He was a Presidential appointee to the Commission of Fine Arts in Washington and was a member during the deliberations that led to building the Vietnam War Memorial and the redevelopment of Pennsylvania Avenue in the 1980s. He also chaired the Public Relations Advisory Committee of the U.S. Information Agency during the second Reagan administration and under President George H.W. Bush.
In more recent years, he was a member of the board of trustees of the Museum of the American Revolution, which is the first museum that relates the entire history of the American Revolution. He was also a member of the Eisenhower Memorial Commission’s Advisory Committee.
Although never engaged in partisan politics, he served as public relations advisor to President Ronald Reagan after he left the White House. He did so on the basis that his services were offered pro bono.
In 2017, at the age of 96, he published his memoir, THE BUSINESS OF PERSUASION: Harold Burson on Public Relations (RosettaBooks).
Burson was married to Bette Foster Burson for one month short of 63 years. He is survived by two sons, Scott F. Burson (Wendy Liebow Burson) of Lexington, Massachusetts and Mark Burson (Ellen Jones Burson) of Westlake Village, Calif., and five grandchildren: Allison Burson, Esther Burson, Wynn F. Burson (Steven Cateron), Holly Burson and Kelly Burson.
Donations may be made to the Boston University College of Communication.
About BCW
BCW (Burson Cohn & Wolfe), one of the world’s largest full-service global communications agencies, is in the business of moving people on behalf of clients. Founded by the merger of Burson-Marsteller and Cohn & Wolfe, BCW delivers digitally and data-driven creative content and integrated communications programs grounded in earned media and scaled across all channels for clients in the B2B, consumer, corporate, crisis management, CSR, healthcare, public affairs and technology sectors. BCW is a part of WPP (NYSE: WPP), a creative transformation company. For more information, visit www.bcw-global.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005550/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
